Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells
Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells
复制标题
DOI：
10.1093/ajcp/aqx092
复制
发表时间：
2017-11-01
影响因子：
3.5
通讯作者：
Zhang, Lizhi
中科院分区：
文献类型：
--
作者：
Lehrke, Heidi D.;Graham, Rondell P.;Zhang, Lizhi
目的：程序性死亡配体1 （PD-L1）在胰腺导管腺癌（PDA）中的表达已经被描述，但未选择的PDA对抗程序性死亡1 (PD-1)/PD-L1治疗的临床反应有限。方法：采用免疫组化方法对24例未分化胰腺癌（UPC）进行PD-L1 （E1L3N克隆）、CD3、CD20、CD68和DNA错配修复蛋白的检测。对载玻片上PD-L1在肿瘤细胞和肿瘤浸润免疫细胞上的表达程度进行评分。结果：PD-L1在UPCs中的表达频率高于pda （63% vs 15%, P < 0.01）。PD-L1在UPCs中的表达程度更大，15例中有13例（87%）含有10%或更多的阳性肿瘤细胞，而7例pda中有3例（P = 0.05）。两组肿瘤均有相似数量的肿瘤浸润性T细胞、B细胞和巨噬细胞。(C)结论：与传统PDA相比，UPC中PD-L1表达的频率和程度都有所增加。抗pd -1/PD-L1药物可能是高侵袭性胰腺癌的一种有价值的治疗方法。
Objectives: Programmed death ligand 1 (PD-L1) expression in pancreatic ductal adenocarcinoma (PDA) has been described, but unselected PDAs have shown limited clinical responsiveness to anti-programmed death 1 (PD-1)/PD-L1 therapy.Methods: We studied 24 cases of undifferentiated pancreatic carcinoma (UPC) using immunohistochemistry for PD-L1 (E1L3N clone), CD3, CD20, CD68, and DNA mismatch repair proteins in this study. Slides were scored for extent of PD-L1 expression on tumor cells and tumor-infiltrating immune cells.Results: PD-L1 expression was more frequent in UPCs than in PDAs (63% vs 15%, P < .01). The extent of PD-L1 expression was greater in UPCs, with 13 (87%) of 15 cases containing 10% or more positive tumor cells compared with three of seven PDAs (P = .05). Both tumor groups showed similar numbers of tumor-infiltrating T cells, B cells, and macrophages.(C)onclusions: UPC is enriched for PD-L1 expression in frequency and extent, relative to conventional PDA. Anti-PD-1/PD-L1 agents may represent a valuable therapeutic approach for this subset of highly aggressive pancreatic carcinoma.